Sarah S Pearlstein1, Marco Salerno2, John A Chabot3, James A Lee3, Jennifer H Kuo4. 1. Department of Surgery, Lenox Hill Hospital, New York, NY, USA. 2. Columbia University Mailman School of Public Health, New York, NY, USA. 3. Department of Surgery, Columbia University Medical Center, 161 Fort Washington Ave, 8th Floor, New York, NY, 10032, USA. 4. Department of Surgery, Columbia University Medical Center, 161 Fort Washington Ave, 8th Floor, New York, NY, 10032, USA. jhk2029@cumc.columbia.edu.
Abstract
BACKGROUND: There is substantial evidence that resecting adrenal metastases can be safely accomplished and extend overall survival in select patients. However, patient access to this operation has not been studied at the population level. The purpose of this study was to determine differences in utilization rates of adrenal metastasectomy (ADMX) across patient populations. METHODS: The Healthcare Utilization Project National Inpatient Sample was used to identify patients who had adrenal metastases (ADM) and who underwent ADMX from 2007 to 2011. Patients were identified by ICD-9-CM diagnosis and procedure codes. Predictor variables included sex, race, median household income, and primary insurance payer. Primary outcomes included receiving an ADMX and same hospitalization mortality. Secondary outcomes included length of stay, infection, cardiac, pulmonary, and renal complications. Univariable and multivariable logistic regression models were used to identify statistical associations. RESULTS: 32,331 ADM and 1070 ADMX patients identified in the database. Despite similar comorbidities, Black patients had 0.30 (95% CI 0.21-0.41) lower odds to receive an ADMX compared to White patients. Medicaid patients had 0.38 (0.28-0.52) less odds and Private Insurance patients 1.18 (1.00-1.39) more odds to receive an ADMX compared to Medicare patients. Women had a 1.39 (1.22-1.58) higher odds ratio of undergoing ADMX compared to men. Of the ADMX cohort, there was no difference in same hospitalization mortality or surgical complications. CONCLUSIONS: Black and Medicaid patients underwent fewer adrenal metastasectomies despite similar comorbidities and postoperative outcomes. This suggests a potential disparity in access to this treatment that disproportionately affects Black and low-income patients, and prompts further study, outreach attempts, as well as, research into improving access.
BACKGROUND: There is substantial evidence that resecting adrenal metastases can be safely accomplished and extend overall survival in select patients. However, patient access to this operation has not been studied at the population level. The purpose of this study was to determine differences in utilization rates of adrenal metastasectomy (ADMX) across patient populations. METHODS: The Healthcare Utilization Project National Inpatient Sample was used to identify patients who had adrenal metastases (ADM) and who underwent ADMX from 2007 to 2011. Patients were identified by ICD-9-CM diagnosis and procedure codes. Predictor variables included sex, race, median household income, and primary insurance payer. Primary outcomes included receiving an ADMX and same hospitalization mortality. Secondary outcomes included length of stay, infection, cardiac, pulmonary, and renal complications. Univariable and multivariable logistic regression models were used to identify statistical associations. RESULTS: 32,331 ADM and 1070 ADMX patients identified in the database. Despite similar comorbidities, Black patients had 0.30 (95% CI 0.21-0.41) lower odds to receive an ADMX compared to White patients. Medicaid patients had 0.38 (0.28-0.52) less odds and Private Insurance patients 1.18 (1.00-1.39) more odds to receive an ADMX compared to Medicare patients. Women had a 1.39 (1.22-1.58) higher odds ratio of undergoing ADMX compared to men. Of the ADMX cohort, there was no difference in same hospitalization mortality or surgical complications. CONCLUSIONS: Black and Medicaid patients underwent fewer adrenal metastasectomies despite similar comorbidities and postoperative outcomes. This suggests a potential disparity in access to this treatment that disproportionately affects Black and low-income patients, and prompts further study, outreach attempts, as well as, research into improving access.
Authors: Natalie Escobio Bustillo; Heather L McGinty; Jason R Dahn; Betina Yanez; Michael H Antoni; Bruce R Kava; Frank J Penedo Journal: Psychooncology Date: 2015-11-09 Impact factor: 3.894
Authors: L Ebony Boulware; Patti L Ephraim; Jessica Ameling; LaPricia Lewis-Boyer; Hamid Rabb; Raquel C Greer; Deidra C Crews; Bernard G Jaar; Priscilla Auguste; Tanjala S Purnell; Julio A Lamprea-Monteleagre; Tope Olufade; Luis Gimenez; Courtney Cook; Tiffany Campbell; Ashley Woodall; Hema Ramamurthi; Cleomontina A Davenport; Kingshuk Roy Choudhury; Matthew R Weir; Donna S Hanes; Nae-Yuh Wang; Helene Vilme; Neil R Powe Journal: BMC Nephrol Date: 2018-05-03 Impact factor: 2.388